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ABSTRACT
The human circulation contains cell-free DNA and non-coding microRNA (miRNA).
Less is known about the presence of messenger RNA (mRNA). This report profiles
the human circulating mRNA transcriptome in people with liver cirrhosis (LC) and
hepatocellular carcinoma (HCC) to determine whether mRNA analytes can be used as
biomarkers of liver disease. Using RNAseq and RT-qPCR, we investigate circulating
mRNA in plasma from HCC and LC patients and demonstrate detection of transcripts
representing more than 19,000 different protein coding genes. Remarkably, the
circulating mRNA expression levels were similar from person to person over the
21 individuals whose samples were analyzed by RNAseq. Liver derived circulating
transcripts such as albumin (ALB), apolipoprotein (APO) A1, A2 & H, serpin A1 & E1,
ferritin light chain (FTL) and fibrinogen like 1 (FGL1) were significantly upregulated
in HCC patient samples. Higher levels of some of these liver-specific transcripts in
the plasma of HCC patients were confirmed by RT-qPCR in another cohort of 20
individuals. Several less abundant circulating transcripts associated with cancer
were detected in most HCC samples, but not in healthy subjects. Liver specificity
of circulating transcripts was confirmed by investigating their expression in HCC
tumor and liver cancer cell lines. Liver specific mRNA sequences in the plasma were
predominantly present outside circulating extracellular vesicles.
Conclusions: The circulating “mRNA” transcriptome is remarkably consistent in
diversity and expression from person to person. Detection of transcripts corresponding
to disease selective polypeptides suggests the possibility that circulating mRNA can
work as a biomarker analyte for cancer detection.

INTRODUCTION

detected in the blood [1–3]. However, detection and
understanding of circulating mRNA sequences is in a
much earlier research phase. Several laboratories have
demonstrated the existence of circulating mRNA in healthy
subjects and those with a disease diagnosis [3–13]. For

We are interested in using mRNA in the blood as
a source of biomarkers of liver disease. Circulating noncoding RNA, such as microRNA (miRNA), is routinely
www.oncotarget.com
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example, circulating hTERT mRNA levels have been
reported to correlate with a diagnosis of hepatocellular
carcinoma (HCC) [14, 15] and with tumor progression [12,
16, 17]. Albumin (ALB) mRNA has also been detected in
the circulation of advanced stage HCC patients and was
reported to predict recurrence of HCC after transplantation
[18, 19]. Additionally, during the preparation of this
manuscript, circulating mRNA in cardiac disease patients
was reported [3]. Although there are reports of specific
mRNAs in select patient populations, a comprehensive
study or “survey” specifically of circulating mRNA
transcripts in liver disease patients has not been conducted.
Circulating mRNA expression profiles, diversity,
consistency, and heterogeneity across individuals is not
clear. Also, the extent to which circulating mRNA is derived
from “non-” blood tissue as opposed to blood or endothelial
cells that line the blood is not clear. mRNA sequences in the
blood, originating from non-blood cells, may be rare and/or
may be representative of pathological events.
In this study, we analyzed total RNA isolated from
adult human plasma. Briefly, RNAseq was performed on
total RNA extracted from the plasma of 10 individuals
with a diagnosis of HCC, 5 individuals with liver cirrhosis
(LC) and no HCC, and 6 individuals with no evidence of
liver disease. Seven of the 10 HCC individuals also had
underlying LC. Protein coding transcripts, or mRNA, were
readily detected in all plasma samples and liver selective
mRNA transcripts were particularly prominent in the
plasma from HCC/LC patients. Some of the circulating
mRNA transcripts corresponded to genes whose
expression is known to be altered or mutated in HCC.
The presence of a selected set of liver specific mRNA
transcripts in the circulation was confirmed by RT-qPCR
analysis of another 20 distinct plasma samples.
Although we are ultimately interested in identifying
circulating mRNA markers of liver disease, this study
primarily intended to determine if there is a circulating
mRNA transcriptome, to identify the extent of its
diversity and consistency from sample to sample, and
to lay the groundwork for methods that can be used to
identify transcripts that correlate with a disease diagnosis.
These parameters of the circulating human liver mRNA
transcriptome are discussed.

both genders and those with HCC and LC with and without
chronic viral hepatitis were included in all liver disease
categories, balance was not achieved with this opportunistic
set. For each sequenced sample, more than 50 million reads
were generated and transcript abundances are reported as
transcripts per million (TPM). Our methods were designed
to reduce ribosomal RNA (rRNA) and mitochondrial RNA
(mtRNA) (Supporting Information). Results of the circulating
transcripts were first organized by abundance (sorted by
highest to lowest TPM in normal plasma) and then highly
abundant transcripts from the top quadrant/upper quartile
were investigated for the frequency of each RNA category.
Among the ~19,000 distinct mRNA transcripts found in
circulation, 65–75% of the coding transcripts represented
the top quartile of all circulating RNA isolated using our
method and this result was consistent across different clinical
categories (Figure 1A). However, when analysis was based
upon the entire transcriptome (instead of just the 75–100%
most abundant transcripts), mRNA represented only 15% of
the identified circulating RNA (Supplementary Figure 1).
It was of interest to track the original tissue source/s of
circulating coding transcripts. Therefore, RNAseq data from
each of the HCC (n = 10), LC (n = 5), and NHC (n = 6)
plasma samples, as well as HCC (n = 2) and normal liver
(n = 1) tissues were analyzed using TissueEnrich software
(see Materials and Methods). The most abundant 1,200
mRNA transcripts were investigated. As shown in Figure 1B,
circulating mRNA in NHC subjects, which included samples
from equal numbers of both genders, contained coding
transcripts from a variety of organs (liver, bone marrow,
stomach, esophagus, prostate). The plasma from those with
HCC and, not surprisingly, normal liver and liver tumor
tissue was greatly enriched for transcripts identified as liver
derived. Of note is that plasma from the 5 individuals with
LC (but no HCC) was reduced in liver derived transcripts.
This result is curious since plasma from people with HCC
was not reduced in liver derived transcripts, yet most (7
of 10) of those with HCC were also diagnosed with LC.
This finding could be an artefact of the small sample size
and not be representative of larger populations or perhaps,
most likely, the presence of HCC influences liver transcript
levels in the circulation. The apparent reduction in amount
of female organ transcripts in the HCC samples reflects the
male gender imbalance in this sample set. Taken together,
these data show that the liver is a major source of coding
RNA (mRNA) present in the circulation. The presence of
liver derived mRNA transcripts in the circulation of HCC
patients provides strong evidence that non-blood mRNA
transcripts can be readily detected in circulation.

RESULTS
Circulating RNA represents diverse transcripts
from various tissues
To evaluate the presence and diversity of mRNA
transcripts in the human circulation, we performed RNAseq
analysis on “total” cell-free RNA from the plasma of 10
individuals with HCC and LC, 5 with LC alone, and 6
“normal” healthy controls (NHC), bringing the total number
of samples analyzed by RNAseq to 21 (Table 1). The HCC,
LC, and healthy individuals were similar in age. Although
www.oncotarget.com
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transcripts show minimal variability between
individuals
The consistency in levels (TPM) of any specific
coding transcript between plasma samples was determined
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Table 1: Plasma samples used for RNAseq

NHC
LC
HCC

n

Age

Gender
n = M/F

HBV/HCV/NAFL/NASH

LC (n)

6
5
10

60.0
59.6
62.7

3/3
5/0
7/3

0/0/0
3/3/0
1/7/2

N/A
5
8

HCC stages (n)
AJCC I, II or
BCLC A, B
N/A
N/A
6

HCC Stages (n)
AJCC III or
BCLC C, D
N/A
N/A
4

Early cancer (AJCC I, II; Barcelona A, B); Late (AJCC III; Barcelona C, D). N/A, Not Applicable. Plasma from 21 different
individuals was used. N = 6, from “normal healthy controls” (NHC), n = 5 from those with a diagnosis of liver cirrhosis (LC)
and n = 10 from those with a diagnosis of hepatocellular carcinoma (HCC) and LC. For the HCC group: 7 of the 10 were also
diagnosed with LC, 2 with NAFL; 6 BCLC A, B or AJCC I, II; 2 BCLC C, D or 2 with AJCC III A & B. Ages and gender
(Male [M], Female [F]), as indicated. Individuals with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) or no
evidence of viral hepatitis were included, as indicated. Diagnosis of HCC, LC and chronic viral hepatitis as in text.
by calculating the fold change of a transcript between the
HCC and NHC samples and between the LC and NHC
samples. Figure 2A is a dot plot comparing log10 (fold
change) between the HCC (n = 10) and NHC (n = 6) patient
plasma and shows that more than 94% of the identified
genes’ expression profiles varied less than 4 to 8-fold

between the cohorts. Figure 2B shows a volcano plot of the
-log10 (fold change) of the variation between HCC (n = 10)
and NHC (n = 6) versus the p-value of the same variation,
and also suggests that the human mRNA transcriptome does
not vary significantly from person to person (genes centered
in the plot), at least for the individuals of differing age,

Figure 1: Profile of RNA present in the circulation. (A) Categories of the most abundant transcripts in the plasma from a cohort

of HCC, LC, and NHC plasma samples. Pie charts represent the proportion of transcript types expressed in the top 25th percentile (75%
to 100% most abundant) of HCC (n = 10), LC (n = 5), and NHC (n = 6) plasma samples. Charts were generated by first identifying the
top 25% abundant transcripts and then counting how often each category appeared. (B) Tissues of origin of mRNA transcripts detected in
human plasma. Five different sample sets were compared: NHC plasma (n = 6), HCC plasma (n = 10), LC plasma (n = 5), normal liver
tissue (n = 1), and HCC tumor tissue (n = 2). The top most 1,200 abundant protein coding genes in each sample category were analyzed
using TissueEnrich software (see Materials and Methods) and compared with tissue specific genes from publicly available RNAseq datasets
(Human Protein Atlas and GTEx using algorithm [49]). Tissue enrichment is expressed as fold change in each category.
www.oncotarget.com
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gender, and clinical condition analyzed here. Remarkably,
the mRNA expression profile for each gene was generally
consistent from person to person.
The consistency of expression profiles was also
reflected in scatter plots with log2 (TPM) values for
the 1,000 most abundant genes from each member of
the NHC, HCC, and LC categories plotted against each
gene’s average log2 (TPM) (data not shown). Consistent
expression profiles were evident when the average log2
(TPM) values of each disease category were plotted
against each other (Figure 2C). Most striking from this
analysis, which includes all 21 plasma samples, was the
consistency in transcript expression, for any given gene,
from sample to sample. It is clear from the scatter plots
that the closer a value plotted to a diagonal line (slope
= 1), the closer it was to the average transcript amount,
which indicated degrees of similarity or departure from
the norm. It is noted that the highly abundant transcripts
varied the least from patient to patient, the HCC patients
had the greatest variability, and the variability was extreme
for a subset of circulating transcripts.
These data collectively suggest that the circulating
human transcriptome is relatively consistent from person
to person, based on samples that range in age, gender, and
liver disease category. That said, even though more than
94% of the gene transcripts between HCC vs. NHC and
LC vs. NHC (data not shown) did not show more than
8-fold variation, there were some differences in mRNA
expression patterns between HCC and healthy subject
samples that offer the possibility of identifying disease
selective biomarker transcripts.

the mean level of expression of each transcript, was
determined and is illustrated using a heat map (Figure
3B). Hierarchical clustering of the expression profiles in
21 plasma samples shows that the HCC samples clustered
together in the heat map (Figure 3B). HCC samples did
appear to selectively have a common subset of elevated
levels of mRNA transcripts. Additionally, some circulating
transcripts selectively upregulated in HCC samples
correspond to genes associated with malignancy and, in
many cases, HCC (e. g., DUSP3 [20, 21], coagulation
factor VII (F7) [22], FAS [23], ITGA9 [24, 25], NBPF12
[26], SNX16 [27], SDF2L1 [28–30], STRA13 [31], TRAP1
[32], SERPINE1 [33]). It is worth mentioning that the
expression levels of 8 different transcripts corresponding
to 5.8S rRNA were highly uniform in all samples analyzed
by RNAseq, underscoring the accuracy and authenticity
of RNAseq analysis and circulating expression profiles
(data not shown). Despite using a method that aimed to
minimize detection of mtRNA and rRNA, we observed
that mitochondrial and ribosomal transcripts were the most
highly abundant mRNA derived transcripts with uniform
expression in the circulation of all individuals and could
have been contributed by any organ or cells present in the
blood (Supplementary Figure 2).

Expression of circulating transcripts in HCC
tumor and HCC cell lines
Figure 1B above demonstrates that a substantial
proportion of transcripts in the plasma of HCC patients
are liver derived. Similarly, HCC tumor associated
transcripts almost exclusively correspond to liver tissue.
RNAseq data strongly suggest increased levels of a subset
of liver specific transcripts in the circulation of HCC
patients. Using the Human Protein Atlas (HPA) tissue gene
expression dataset, which includes expression levels from
37 human tissues based on RNAseq, we identified a set of
transcripts that are very selective for liver tissue, including
ALB, HP, APOA2, APOH, SERPINA1, ORM1, and HPX.
The genes’ extreme liver specificity is demonstrated
in Figure 4A. The levels of these transcripts were then
experimentally determined in a set of liver cancer cell
lines and a moderately differentiated human tumor
tissue (HCC103T) using RT-qPCR and are illustrated in
Figure 4B. Expression levels were normalized with levels
of corresponding transcripts in immortalized nonmalignant
PH5CH liver cells. Our data demonstrate significant
overexpression (p < 0.01) of these transcripts in tumor
tissue, as well as cancer cell lines (Figure 4B).

Liver derived mRNA sequences are among the
most abundant transcripts in circulation
Although most of the circulating coding transcripts
did not vary significantly in expression from person
to person (Figure 2), some features of the expression
analysis are notable. The detection of mRNA transcripts
in the plasma that correspond to polypeptides derived from
or enriched in the liver, such as ALB, APOA1, APOA2,
APOB, APOH, SAA2, SERPINA1, SEPP1, ORM2, etc.
(Figure 3A), and from other non-blood cells was striking
and provides evidence that the circulation contains
mRNA that originated in the liver and not from artefacts
of the phlebotomy process. These liver derived transcripts
were upregulated in the circulation of HCC patients
as compared to those with LC. Figure 3A represents
expression patterns (log2 (TPM)) of some abundant (base
mean TPM between 200 (AGT) and 9133 (ALB)) liver
derived transcripts reflecting 3 to 7-fold higher levels
compared to those of LC patients (p < 0.01).
A subset of 50 circulating transcripts was identified
for their differential expression between HCC and NHC
groups and between LC and NHC groups. Briefly,
the expression levels of the 50 transcripts, relative to
www.oncotarget.com
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RT-qPCR
To validate the presence of specific transcripts
in patient circulation, we investigated a set of clinical
samples that were studied earlier by RNAseq. RT2229
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qPCR assays were carried out on circulating RNA
from HCC patients (n = 4) and age and gender matched
healthy controls (n = 4), and expression profiles of six
liver derived transcripts were studied (Supplementary
Figure 3). Data showed consistent expression profiles
using RNAseq and RT-qPCR. Validation of circulating
transcripts allowed for testing of specific mRNA
transcripts in an additional independent set of samples
from 20 individuals (10 with a diagnosis of HCC and
10 age and gender matched healthy subjects). In these
20 samples, the prevalence of 4 circulating liver specific
transcripts, FTL, APOA2, SERPINA1, and ALB, was
examined by RT-qPCR using exon specific primers
(Supplementary Table 1). Figure 5A shows the results as
average cycle threshold (Ct) values in samples from the
HCC patients and NHCs. Ct values reflect the number of
PCR cycles required for the fluorescent signal from the
amplified product to cross a threshold or background.

Primers specific for exons generated detectable products
relatively consistent in amount from patient to patient.
However, consistent with RNAseq data from the
previous cohort, the transcripts tested were generally
significantly upregulated in HCC samples as compared
to the healthy subjects. Relative expression in HCC
patients was calculated by normalizing with the Ct values
of an internal reference control and also those of age and
gender matched NHCs (Figure 5B). Figure 5B represents
the same data as relative expression of APOA2, ALB,
FTL, and SERPINA1 transcripts in each HCC patient
sample in comparison to the average amount present
in the NHCs (n = 10). Again, although the number of
patient and healthy subject samples analyzed are too
small to draw conclusions, the trends of elevated levels
of these transcripts in HCC samples relative to healthy
subjects observed with the sample sets used in RNAseq
does seem to be sustained. Indeed, some HCC samples

Figure 2: Human circulating transcriptome is essentially similar from person to person. (A) Transcript abundance (TPM)

corresponding to each of ~19,000 coding regions in each sample as a function of fold difference from the mean of all samples. Plot of
log10 (fold change) of the variation between HCC (n = 10) and NHC (n = 6) for each gene. (B) Volcano plot of the -log10 (fold change) of
the variation between HCC (n = 10) and NHC (n = 6) vs. the p-value of the same variation. Genes toward the center of plot do not show
significant variation, while those that are spread out show significant differences in terms of TPM. (C) The 1,000 most abundant circulating
transcripts corresponding to protein coding genes graphed for each sample subset. Comparison of average gene expression (log2 (TPM)) of
the top 1,000 transcripts between HCC vs. NHC, HCC vs. LC, and LC vs. NHC categories.
www.oncotarget.com
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Figure 3: Expression profiles of unique circulating transcripts in liver disease. (A) Expression profiles (log2 (TPM)) of some

abundant liver derived circulating transcripts with 3 to 7-fold higher expression in HCC samples compared to LC samples (p < 0.01). (B)
Hierarchical clustering of differentially expressed genes. Differentially expressed transcripts were identified by sorting the normalized
TPMs around the mean (zero) such that the scaled TPM values for HCC vs. NHC and LC vs. NHC are opposite in signs (negative, low
expression and positive, high expression) and the difference between group averages was at least (± 1.5). The TPM values were scaled for
each gene with the formula (x-µ)/σ, where x is variable data point, µ and σ are the average and standard deviation for a gene, respectively,
with color scheme YlOrRd (yellow, orange, red).
www.oncotarget.com
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had 9 to 20-fold elevations in liver specific transcripts
compared to LC samples.

predominantly correspond to exonic regions and that
certain specific regions within exons are detected at a
higher sequencing depth than other regions within a
given transcript. To confirm the selective detection
of exons in liver derived transcripts, nested semiquantitative PCR was performed on total, cell-free,
DNase-treated RNA isolated from patient samples.
Primers for APOA2 that amplify either intronic or
exonic sequences (that span the intron) were used. Our
data show the detection of exon specific products alone
without any intron specific or intron containing PCR
products (Figure 7A). Further, detection of APOA2
and FTL transcripts in patient plasma samples was also
validated by nested PCR and LICOR 800 probe based
Southern blotting (Figure 7B, Supplementary Table 1).
The sensitivity of amplicon product detection increased
when mRNA was either amplified using nested PCR
or hybridized to gene specific probes via Southern blot

Liver derived circulating transcripts
predominantly map to genomic exons and
represent mature mRNA
If the RNA sequences detected in the circulation
were derived from mRNA, the transcripts should
align with genic exons and lack intronic sequences
as introns are not present in most mature mRNA. We
analyzed the read piles for 6 liver derived transcripts
from at least 10 individuals (5 HCC, 5 NHC) and found
substantial representation of exons in sequencing reads.
As an example, Figure 6 shows read pile profiles of
three circulating mRNA transcripts (APOA2, FTL, and
SERPINA1) in 8 distinct plasma samples. The data
show that the sequencing reads of circulating transcripts

Figure 4: Liver specificity of circulating transcripts investigated in Human Protein Atlas (HPA) dataset, HCC tumor,
and cell lines. (A) Expression profiles of transcripts were evaluated in HPA dataset (version 19.2, Ensemble version 92.38) representing

expression levels in 37 human tissues based on RNAseq. Y-axis reflects expression in transcripts per million (TPM). (B) Relative expression
of some liver specific transcripts was investigated in a tumor tissue (HCC103T) and cancer cell lines HepG2 and Huh7. Expression profiles
were normalized with GAPDH expression and expression in non-malignant PH5CH liver cells. Each RT-qPCR reaction was carried out at
least in triplicate and data are represented as mean values. Significant upregulation in comparison to control PH5CH cells is reflected by
asterisk sign (p < 0.01).
www.oncotarget.com
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Liver derived transcripts predominantly
detected outside extracellular vesicles (EVs) in
circulation

(Figure 7B lower panel). Detection of a set of liver
derived circulating transcripts in HCC plasma samples
was also demonstrated using nCounter Elements assay
(Nanostring technology), which directly measures mRNA
transcripts without the need for reverse transcription and
PCR amplification (data not shown).

Extracellular vesicles (EVs) consisting of
exosomes and microvesicles (MVs) are small membrane-

Figure 5: Validation of liver derived circulating transcripts by RT-qPCR in an independent dataset. (A) Relative

expression of liver specific circulating transcripts in a cohort of 10 HCC patients compared to 10 age/gender matched normal healthy
control (NHC) samples was investigated by RT-qPCR. Average Ct values in HCC and NHC samples are plotted. Statistical significance was
calculated by unpaired Student’s t-test. (B) Relative expression calculated by ∆∆Ct method. ∆Ct values of HCC samples were calculated by
subtracting spike-in ultramer Ct from Ct of target transcripts. Ct values of 10 NHC samples were averaged and normalized with respective
ultramer Ct values to get an average NHC ∆Ct. ∆∆Ct of HCC samples was calculated by subtracting average NHC ∆Ct from each HCC
sample ∆Ct. Relative expression calculated by formula 2-∆∆Ct plotted as bar graphs. Each qPCR reaction was run at least in triplicate and data
are represented as mean values. Sequence of oligos used can be found in Supplementary Materials and Methods.
www.oncotarget.com
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The results show that although transcripts such as MTCO2, FTL, TMSB4X, HBA1, and other mitochondrial and
ribosomal transcripts were uniformly present inside and
outside circulating EVs, liver specific transcripts were
predominantly abundant in the EV-free fraction. Bar
graphs (Figure 8D) highlight the differential expression
(TPM) of circulating transcripts. The results suggest that
major tissue specific transcripts are predominantly present
in plasma outside vesicles. Figure 8E shows a snapshot
of read piles of four circulating transcripts including liver
specific APOA2 and SERPINA1 in EV/EV-free fractions
and total unfractionated plasma. Note that FTL and HBA1
transcripts are represented in both fractions, while APOA2
and APOE are preferentially detected in EV-free plasma,
highlighting the differential expression. It is tempting to
speculate that these transcript fragments might exist as
protein nucleic acid complexes that ensure protection from
ubiquitous nucleases in the circulation.

enclosed particles of endosomal and plasma membrane
origin, respectively, that are released by cells into the
extracellular environment. These membrane-bound
vesicles represent an important mode of intercellular
communication. miRNA and other “cargo” from
intracellular compartments, expressed in the circulation,
have been reported to be contained within EVs (reviewed
in Couto et al. [34]). It has been suggested that circulating
EVs can be used as noninvasive biomarkers for early
detection, diagnosis, and treatment of cancer [35]. Our
analysis on plasma, so far, used methods that did not
distinguish between mRNA contained within or outside
of EVs. It was therefore of interest to determine if the
circulating transcripts are located within EVs or circulate
as membrane-free molecules (EV-free).
To optimize the purification of EVs in plasma
samples, we first evaluated EV isolation from liver cancer
cell lines. Figure 8A shows the enrichment of unique EV
markers CD9, CD63, CD81, and Alix by immunoblotting.
EV isolation was then carried out with HCC and LC patient
plasma samples and further characterization carried out by
nanoparticle tracking analysis (NTA) and immunoblotting
(Figure 8B, 8C; Supplementary Figure 4). NTA of these
samples confirmed particle size ranges between 50 to 150
μm, which are specifically characteristic of exosomes
(Figure 8C). RNA was isolated from total plasma and
two plasma sub-fractions, EV and EV-free, from the same
patient (HCC101P) and followed by RNAseq analysis.

DISCUSSION
Here we show that human plasma, among a diverse
family of RNA transcripts, contains mRNA corresponding
to more than 19,000 different coding genes. The differential
sequencing depths and read pile densities within exons
suggest that circulating mRNA transcripts likely exist as
fragments. Investigation into the contents of circulating
EVs implied that mRNA transcripts are located within and

Figure 6: Circulating transcripts predominantly map to genomic exons. RNAseq read piles in plasma samples from 4 HCC
patients and their age and gender matched normal healthy controls (NHC) analyzed in a single flow cell experiment. Alignment to 3 genes
in 8 samples is shown and suggests that circulating transcript sequences overwhelmingly align to exons and not introns. Histograms show
relative distribution of detected mRNA reads. Specific regions within exons show higher sequencing depth than others and patterns are
largely consistent across samples. RefSeq gene model diagrams shown at bottom of read piles.
www.oncotarget.com
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outside EVs. Many of these coding transcripts came from
the liver and other solid organs, and liver derived transcripts
were predominantly found outside circulating EVs. One
unique observation is that the level of any circulating
mRNA transcript was very similar from patient to patient,
not varying by more than 8-fold for 94% of the different
gene transcripts, which suggests that the circulating human
mRNA transcriptome is remarkably consistent.
We demonstrate the upregulation of cancer specific
transcripts in the circulation of HCC patients compared to

LC patients. Consistent with our results, a growing body
of evidence exists supporting the presence of circulating
mRNA in various cancer patients [11, 12, 36]. Serum
hTERT mRNA in HCC patients correlated with clinical
variables such as tumor size, number, and degree of
differentiation [14]. A multi-centered trial demonstrated
the sensitivity/specificity of HCC diagnosis by hTERT
mRNA as 90.2%/85.4% and indicated that it was superior
to AFP, AFP-L3, and DCP in the diagnosis of HCC [15].
Similar performance using serum hTERT mRNA was

Figure 7: Characterization of circulating transcripts using semi-quantitative nested PCR and Southern blotting. (A)

APOA2 gene consisting of 4 exons was studied in two clinical samples, HCC11 (cancer patient) and NHC10 (normal healthy control)
using 100 ng cDNA in each reaction. Two oligo sets were prepared: one set encompassing regions of exon 3 and exon 4 and the other
set corresponding to the intervening intron (amplifying an 82 bp fragment). A short product of 76 bp was expected to be amplified by the
former oligo set if no intron was present between the exons in the amplified fragment. Genomic DNA or even unspliced mRNA would yield
a 470 bp product. Visualized gel demonstrates that the 76 bp APOA2 product corresponding to primers spanning exons 3 and 4 is detected
and shows higher expression in HCC11 sample compared to NHC10, but intron specific primers do not yield any product. HepG2 cDNA
was used as a positive control. (B) Two sets of primer pairs, corresponding to PCR1 extended amplicon and nested amplicon were used
to amplify APOA2 and FTL transcripts in two samples, HCC19 and NHC18. PCR1 was carried out for 30 cycles using extended PCR1
oligos. PCR1 product was diluted 12.5-fold and subjected to nested PCR using nested oligos. Products were separated by electrophoresis
on a 2% agarose gel. PCR1 products could not be detected, but the nested APOA2 (47 bp) and FTL (49 bp) products were clearly observed.
HepG2 cDNA was used as a control. As expected, the inner nested oligo sets yielded smaller products (47 bp for APOA2, 49 bp for FTL),
while outer PCR1 sets of oligos yielded a larger product (76 bp for APOA2, 113 bp for FTL). Gel resolved PCR1 and nested PCR products
were transferred to a nylon membrane followed by hybridization with extended PCR1 specific 5′-LICOR 800 tagged oligos. As expected,
5′-LICOR 800 probes did not detect the nested products. The positive control in lane 1, using PCR1 extended primer set and HepG2 cellular
cDNA as template, reflects the extended PCR1 products of these transcripts. Lanes 2 and 3 are no template negative controls with either
extended PCR1 (lane 2) or nested (lane 3) oligos. Lanes 4 and 6 reflect the extended PCR1 products in two patients, while lanes 5 and
7 represent nested products that are not detected by Southern blot using 5′-LICOR 800 tagged oligos in the same samples. Sequences of
oligos can be found in Supplementary Materials and Methods.
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demonstrated in breast cancer [17, 37]. Albumin mRNA
has also been detected in the peripheral blood of advanced
stage (TNM stages III and IV) HCC patients. While it has
been reported that liver transplantation in HCC patients
reduced albumin mRNA below detectable limit, recurrence
of HCC led to detectable levels of circulating albumin
mRNA. No circulating albumin mRNA was detected in
healthy individuals or cirrhotic liver patients [38]. Higher
levels of plasma albumin mRNA were also detected in LC
and active hepatitis B patients with a diagnostic sensitivity
of more than 85% and specificity for detection over 90%
[39]. Together, these reports clearly highlight the potential
of circulating RNA in the detection of HCC.

Although the numbers of HCC/LC patients
represented in our study are too small for conclusive
statements to be made about the prevalence or correlation
of specific transcripts with any clinical states, we
observed striking trends. Plasma samples from HCC
patients contained elevated amounts of specific mRNAs
and these samples were “grouped together” by the
unsupervised analysis of the RNAseq data. Since the
genes and polypeptides for many of these mRNAs (such
as ALB, DUSP, FAS, SDF2L1, STRA13, MGAT2) have
been reported elsewhere in the literature to be associated
with HCC [15, 20, 29, 40], it is tempting to suggest that
their presence as mRNA in the circulation is related to the

Figure 8: Circulating liver derived transcripts predominantly exist outside extracellular vesicles (EVs) in the plasma of
HCC patients. (A) EVs were isolated from the culture media of HepG2 and Huh7 liver cancer cells and characterized by western blotting.

Equal amounts of protein samples were loaded and the enrichment of tetraspanin receptors CD9, CD63, CD81, Alix, and TSG101 was
tested as markers of EVs. (B) EVs from either HCC, LC, or normal healthy control (NHC) plasma samples were extracted using ExoQuick
kit and further purified using ultracentrifugation. In addition to EV markers Alix, CD63, and CD81, liver specific marker SERPINA1 was
investigated. FAK was used as a loading control. (C) Characterization of EVs from various plasma samples was done by NTA NanoSight
NS300 system and NTA software analysis was used to obtain the size distribution and quantitation of particles. (D) Plasma sample from
an HCC patient (HCC101P) was fractionated into EV fraction and remaining EV-free fraction. RNAseq analysis was carried out on RNA
from total plasma and its two fractions. Comparative expression profiles (TPM) of circulating transcripts within and outside EVs for more
than 20 liver derived transcripts are shown. (E) Read piles of some of the liver specific transcripts shown above in 6D for whole patient
plasma, EVs, and EV-free fraction highlight the differential expression. FTL and HBA1 show almost equivalent levels of transcripts within
and outside EVs, but APOA2 and APOE preferentially exist outside EVs.
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cancer diagnosis, despite the small numbers of samples
used in this study.
Our data indicate that liver derived transcripts are
predominantly present outside EVs. Endothelial cells in
many blood vessels form an uninterrupted vasculature.
However, as illustrated in Figure 9A, the discontinuous
architecture and fusion of the luminal and abluminal
plasma membrane at fenestrae, also called ‘gaps,’ of
liver sinusoidal endothelial cells (LSECs) constitute a
permeable barrier between blood cells on one side and
hepatocytes and hepatic stellate cells on the other side,
making them the most permeable endothelial cells of
the mammalian body [41]. Further, the endothelium
is thickened in HCC and loses its fenestrations while a
discontinuous basement membrane is formed, resulting
in vessels that are structurally and functionally abnormal
[42]. It could be speculated that due to this known leaky
vasculature in liver and other endocrine organs, detection
of tissue specific circulating transcripts is not surprising.
The ability to detect mRNA in the blood could
offer another non-invasive biomarker analyte and a
liquid biopsy platform to detect and risk stratify disease,

providing advantages to current non-invasive methods
(Figure 9B). Primarily, it might be possible to detect
mRNAs corresponding to non-secretory polypeptides in
the blood or gene products that are present in extremely
low abundance and cannot be detected with antibody
assays. Also, detection of mutant genes and gene
products is possible and, unlike mutated DNA that is
usually single or limited copy number per cell, RNA is
amplified. We have investigated the circulating human
mRNA transcriptome and demonstrated dysregulation
of certain liver and cancer specific mRNA transcripts in
the circulation of HCC patients. However, more work is
needed to determine biological significance and establish
a biomarker value of mRNA signatures in HCC clinical
management.

MATERIALS AND METHODS
Human subjects
Human plasma samples used in this study were
from the Corporal Michael J. Crescenz VA Hospital,

Figure 9: Schematic representation of liver sinusoids and loose architecture of liver endothelium. (A) Liver sinusoids.

Sinusoids are highly modified leaky fenestrated capillaries with large lumens found in the liver, bone marrow, lymphoid tissue, and in some
endocrine organs. The discontinuous architecture and fusion of the luminal and abluminal plasma membrane at fenestrae or gaps of liver
sinusoidal endothelial cells (LSECs) result in leaky endothelium. This leaky vasculature may contribute to the transport of cellular cargo,
extracellular vesicles (EVs), and large molecules like RNA-protein complexes from liver cells into blood. (B) mRNA signatures as potential
liver disease biomarkers. The leaky endothelium provides an opportunity for development of a liquid biopsy platform for liver diseases,
including hepatocellular carcinoma, where patient plasma can be tested for the presence of certain disease specific transcripts as biomarker
analytes and can be effectively used in patient management.
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Philadelphia, PA (CMCVAMC); the University of Texas,
Houston, TX; and a commercial supplier, BioChemed
Services, Inc., Winchester, VA. RNAseq was carried out on
plasma samples from CMCVAMC and BioChemed. Patient
characteristics are summarized in Table 1 and explained
in detail in Supporting Materials and Methods. RT-qPCR
validation was performed on HBsAg positive HCC
patients, ages 45–75 years (n = 10), and HBsAg/HCC/LC
negative age and gender matched individual controls (n =
10) from University of Texas, Houston. Plasma samples
and, in some cases, parallel tumor tissues from BioChemed
were derived from both males and females (aged 57–74),
with HCC histologically confirmed and staging provided.
All samples used in our study were collected with informed
consent in writing under IRB approved protocols.

Total RNA was also extracted from two Grade-2 HCC tumor
tissues (HCC103T, HCC105T, BioChemed) and a normal
liver tissue using mirVana miRNA Isolation Kit (Ambion,
Austin, TX, USA). All kits were used by following
manufacturer guidelines. Tumor samples corresponding to
two plasma samples (HCC103P, HCC105P, BioChemed)
were investigated by RNAseq and one of them (HCC103T)
was also studied by RT-qPCR. 100 mg tissue treated with
RNAlater-ICE solution (Invitrogen, Carlsbad, CA, USA)
was homogenized in a glass homogenizer, worked-up
following kit protocol, and RNA eluted in 100 µl RNasefree water. Plasma (3 ml) from HCC101P (BioChemed) was
spun at 2,000g for 15 minutes to remove cellular debris and
supernatant was collected. Total RNA from extracellular
vesicles (EVs) was extracted using the ExoMir Kit
(BIOO Scientific Corp., Austin, TX, USA). RNA from the
remaining EV-free flow-through plasma was extracted using
the Qiagen RNeasy Serum/Plasma Kit (Qiagen, Valencia,
CA, USA). RNA from plasma EVs, EV-free plasma, and
liver tissues was sequenced at TJU as described above.

RNAseq experiment and analysis
Total RNA from 1–2 ml plasma samples (spun
at 2,000g for 5 minutes) was prepared using the Qiagen
RNeasy Serum/Plasma Kit (Qiagen, Valencia, CA, USA)
and quantified on a NanoDrop spectrophotometer. RNAseq
analysis was carried out at Cancer Genomics Facility at
Thomas Jefferson University (TJU), Philadelphia, PA,
USA. RNA purity and integrity was assessed by Agilent
2100 BioAnalyzer. Libraries were prepared using the
SMARTer® Stranded Total RNA-Seq Kit v2 (Takara Bio
USA, Inc., Mountain View, CA, USA). Paired-end sequence
reads were analyzed according to currently available best
practices for whole-transcriptome analysis, which include
alignment onto the current human reference genome
assembly (GRCh38) using the STAR splice aware aligner.
Transcript counts and abundances expressed in transcripts
per million (TPM) were estimated based on GENCODE
v28 gene annotations using the RSEM algorithm.
Differential expression between groups was tested with the
R/Bioconductor DESeq2 package. Tissue specific content
was generated using the R/Bioconductor TissueEnrich
package [43] (see Supporting Materials and Methods).
Read piles of liver specific transcripts were analyzed using
alignment .bam files corresponding to genome version
GRCh38. The coverage density plots showed how many
reads were aligned to a specific location, typically lining
up with exon boundaries. Detailed information is provided
in Supporting Materials and Methods. Tissue specificity of
transcripts was also evaluated using Human Protein Atlas
(HPA) dataset (version 19.2, Ensemble version 92.38),
representing expression levels in 37 human tissues from
122 individuals based on RNAseq [44].

RT-qPCR
RNA samples from cell lines and tumor tissue (2.5
µg) were subjected to DNase digestion before reverse
transcription to cDNA. 50 ng qPCR reactions were
set in triplicate using LightCycler 480 SYBR Green I
Master reaction mix and LightCycler 480 System (Roche
Diagnostics, Indianapolis, IN, USA). ∆Ct values were
calculated by subtracting Ct values of GAPDH in each
sample from Ct values of target genes. ∆Ct values of tumor
and HCC cell lines were normalized with ∆Ct values of liver
PH5CH cells to yield ∆∆Ct values and relative expression
was calculated using the formula 2-∆∆Ct. RNA from clinical
plasma samples (1 to 2 ml) was prepared using the Qiagen
RNeasy Serum/Plasma Kit (Qiagen, Valencia, CA, USA).
RNA was subjected to DNase digestion before reverse
transcription to cDNA. Each cDNA sample was spiked
with specific copy number of a 102 nt zebrafish-specific
DNA ultramer (IDT, Coralville, IA) for use as internal
control. PCR reactions for each sample (n = 20) with 25
ng cDNA were subjected to qPCR. Primers were designed
corresponding to high sequencing depth regions identified
from RNAseq (Supplementary Table 1). Relative expression
of each transcript was calculated using the ∆∆Ct method by
normalizing with internal reference DNA ultramer and the
average ∆Ct value (n = 10) from age and gender matched
NHC samples. Each PCR reaction was carried out in
triplicate sets and relative expression determined.

RNA extraction from cell lines, tissues,
extracellular vesicles (EVs), and EV-free plasma

Semi-quantitative nested PCR and Southern blots
Clinical plasma samples from HCC patient HCC11
and NHC10 were investigated for liver derived APOA2
mRNA. Two sets of oligos were designed. One oligo set had
forward/reverse primers specific for APOA2 exon 3/exon 4,

Total RNA was extracted from HCC cell lines HepG2
and Huh7 and immortalized normal liver PH5CH cells using
Qiagen miRNeasy Mini Kit (Qiagen, Valencia, CA, USA).
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respectively, and amplified a short product of 76 bp when no
intron was present in the transcript. The other set consisted
of oligos specific for the intervening intron between exons
3 and 4 and amplified an 82 bp fragment. Semi-quantitative
PCR reactions were carried out using either exon 3 and 4
specific oligos or oligos corresponding to the intervening
intron. PCR was carried out for 30 cycles and products were
resolved by electrophoresis on a 2% agarose gel. For further
validation and characterization of circulating transcripts,
nested PCR in clinical plasma samples was carried out
(HCC patient HCC19 and NHC18) to study APOA2 and
FTL transcripts. Two sets of oligos, corresponding to
PCR1 extended amplicon and nested amplicon, were used
to amplify APOA2 and FTL cDNA. PCR1 was carried out
for 30 cycles using extended PCR1 oligos. PCR1 product
was diluted 12.5-fold and subjected to additional 30 cycle
nested PCR using nested oligos. Both PCR1 and nested PCR
products were resolved by electrophoresis on a 2% agarose
gel. Outer PCR1 oligo sets yield a larger product (76 bp for
APOA2, 113 bp for FTL), while inner nested oligo sets yield
smaller products (47 bp for APOA2, 49 bp for FTL). PCR1
and nested PCR products were transferred to an Amersham
Hybond-N+ membrane (GE Healthcare Life Sciences,
Marlborough, MA, USA) followed by hybridization with
extended PCR1 specific 5′-LICOR 800 tagged oligos (IDT,
Coralville, IA, USA) for Southern blot based detection of
PCR amplified transcripts. 5′-LICOR 800 probes incorporate
in PCR1 products, but not in nested products.

probed with either rabbit monoclonal antibodies (mAbs)
to TSG101 (ab125011) from Abcam (Cambridge, UK)
and CD63 (55051) and FAK (13009) from Cell Signaling
Technologies (Danvers, MA, USA) or mouse mAbs to
human CD81 (ab23505) from Abcam, Alix (sc53540) and
human CD9 (sc13118) from Santa Cruz Biotechnology,
Inc. (Dallas, TX, USA), and human SERPINA1 (NBP252557) from Novus Biologicals (Littleton, CO, USA).

Statistical analysis
The reads for each mRNA obtained from the plasma
of HCC, LC, and NHC patients were analyzed in separate
generalized linear models with the assumption of negative
binomial (NB) distribution using the DESeq2 software
package. The p-values for each set of tests were adjusted
for multiple testing using the False Discovery Rate (FDR)
of 1%. RT-qPCR data are shown as mean values and
considered statistically significant at p < 0.05. GraphPad
Prism software (San Diego, CA, USA) was used for
analysis. Western and Southern blot figures were assembled
in Adobe Photoshop (Adobe Inc., San Jose, CA, USA).

Abbreviations
HCC: Hepatocellular carcinoma; LC: Liver
cirrhosis; miRNA: microRNA; mRNA: messenger
RNA; RNAseq: RNA sequencing; RT-qPCR: Reverse
transcription-quantitative polymerase chain reaction;
NHC: Normal healthy control; EVs: Extracellular vesicles;
MVs: Microvesicles.

Isolation and characterization of EVs
EVs were purified from HepG2 and Huh7 liver
cancer cell lines as previously described [45, 46] with some
modifications. Briefly, the culture supernatant was collected
after 48 hours of starvation, pre-cleared of any cellular
debris at 2,000g for 20 minutes at 4°C, and centrifuged
again at 10,000g for 30 minutes at 4°C. The supernatant
was ultracentrifuged at 100,000g for 120 minutes at 4°C.
The EV pellet was washed in phosphate buffered saline
(PBS) at 100,000g for 120 minutes at 4°C and resuspended
in PBS. Plasma samples (1 to 1.5 ml) from HCC patients
and normal healthy controls (CMCVAMC) were spun
at 2,000g for 30 minutes to remove cellular debris
before purification of EVs using ExoQuick kit (System
Biosciences, Palo Alto, CA, USA). EVs were further
purified by ultracentrifugation using PBS at 100,000g for
120 minutes at 4°C. EV pellet was resuspended in PBS and
quantified using NanoSight Tracking analysis (Malvern
Instruments, Malvern, UK). Remaining EV suspension was
lysed for further characterization. Additional details are in
Supporting Materials and Methods.
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